QIAGEN and Clinical Genomics partner on liquid biopsies to monitor patients for recurrence of colorectal cancer
(WorldNews Netherlands)

Hilden, Germany; Germantown, Maryland; and Bridgewater, New Jersey, August 21, 2017 -QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced they have implemented the PAXgene Blood ccfDNA Tube* sample collection in Clinical Genomics` ColveraTM colorectal cancer (`CRC`) recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate monitoring for recurrence of colorectal cancer with a simple blood test collected in a physician`s office. `The Colvera test represents a unique opportunity for convenient, non-invasive monitoring of...